Cambridge Enterprise, University of Cambridge
Cambridge Enterprise exists to help University of Cambridge inventors, innovators and entrepreneurs make their ideas and concepts more commercially successful for the benefit of society, the UK economy, the inventors and the University.
|Telephone:||+44 (0)1223 760 339|
|Address:||Hauser Forum, 3 Charles Babbage Road, Cambridge|
|Membership type:||Cambridge University Department|
Cambridge Enterprise offers support to all of the University’s research fields, from science, technology, engineering, maths and medicine to the arts, humanities and social sciences. It is through us that many of the University’s inventions and ideas are protected, licences and consultancy contracts are negotiated, and funding is acquired by start-ups and spin-outs.
Morphogen-IX Ltd, a biotechnology spin-out from Cambridge Enterprise that is focused on the development of bone morphogenetic proteins (BMPs) for the treatment of pulmonary arterial hypertension (PAH), announced the nomination of its clinical development candidate and initiation of formal preclinical development.
4 December 2018Read in full
Poro Technologies, which is developing next-generation LED technology, has won the £20,000 first prize in the 2018 Cambridge Enterprise and Entrepreneurial Postdocs of Cambridge (EPOC) Postdoc Business Plan Competition.
6 November 2018Read in full
Astellas Pharma Inc. and Quethera Limited have announced that Astellas has acquired Quethera, a gene therapy company headquartered in the United Kingdom that is focused on developing novel treatments for ocular disorders, such as glaucoma.
14 August 2018Read in full
Twelve semi-finalists have been named in the 2018 Postdoc Business Plan Competition run by Cambridge Enterprise in conjunction with the Entrepreneurial Postdocs of Cambridge (EPOC).
1 August 2018Read in full
Morphogen-IX Ltd, a preclinical biotechnology company focused on the development of bone morphogenetic proteins for the treatment of pulmonary arterial hypertension (PAH), has announced the appointment of Professor Nick Morrell as CEO. Morrell co-founded the company in 2015 based on research from his lab at the University of Cambridge.
9 July 2018Read in full
Silicon Microgravity (SMG), a spin-out from both BP and the University of Cambridge, has raised $7 million from IP Group, Parkwalk, BP Ventures and Cambridge Enterprise.
12 June 2018Read in full
Microbiotica, a Cambridge Innovation Capital portfolio company, has entered into a multi-year strategic collaboration with Genentech worth up to $534 million. The companies will work together to discover, develop and commercialise biomarkers, targets and medicines for inflammatory bowel disease (IBD).
7 June 2018Read in full
Cambridge Enterprise, the Cambridge Angels and Cambridge Capital Group have completed an initial round of investment in Sorex Sensors Limited, a spin-out company from the Department of Engineering at the University of Cambridge.
4 June 2018Read in full
Cambridge Enterprise, the research commercialisation arm of the University of Cambridge, has signed an agreement with one of China’s largest universities to encourage innovation and entrepreneurship in one of China’s fastest-growing high-tech clusters.
1 June 2018Read in full
An annual data review published by Global University Venturing reports that University of Cambridge spin-outs raised $2,216m in capital for 2013-17, putting it at the top of the global list of universities. The article also reports that in this period Cambridge’s spin-outs closed 96 deals, making it second only to Stanford University in total number of deals, though ahead of it in total capital raised.
29 May 2018Read in full
Ceres Agri-Tech Portfolio Manager/ Director
We are looking for Ceres Agri-Tech Portfolio Manager(s) / Director(s) (depending on experience) to work across the Ceres partner...